Zosano gets Crucial FDA Nod for New Drug Application for Qtrypta™ for Acute Treatment of Migraine
Zosano Pharma (NASDAQ: ZSAN), a clinical-stage biopharmaceutical Company, announced the acceptance of the Company’s New Drug Application for Qtrypta™, a proprietary formulation of Zolmitriptan by the U.S Food and Drug Administration (FDA) for filing and substantive review. The FDA has set a The Prescription Drug...
